Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | PHGDH | O43175 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2119388 | 0.81 | KDM4E (0.50) | LMNAMEN1KMT2AMAPTGAA | |
| SCHEMBL611620 | 0.81 | CA12 (0.41) | MEN1KMT2AMAPTHTTALDH1A1 | |
| SCHEMBL21960887 | 0.80 | BRD4 (0.43) | LMNAMEN1KMT2AMAPTGAA | |
| SCHEMBL17796618 | 0.80 | BRD4 (0.40) | LMNAMEN1KMT2AMAPTGAA | |
| SCHEMBL3058408 | 0.80 | HTT (0.38) | LMNAMEN1KMT2AMAPTGAA | |
| SCHEMBL21964597 | 0.77 | MEN1 (0.39) | LMNAMEN1KMT2AMAPTGAA | |
| SCHEMBL21960852 | 0.76 | GABRA5 (0.46) | MEN1KMT2AHTTALDH1A1 | |
| Hydrochloric Acid SCHEMBL28959660 | 0.74 | PRSS1 (0.37) | LMNAMEN1KMT2AMAPTGAA | |
| SCHEMBL8568508 | 0.74 | SMN1; SMN2 (0.56) | BAZ2BLMNAMEN1KMT2AGAA | |
| SCHEMBL18029670 | 0.74 | LMNA (0.46) | LMNAMEN1KMT2AMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022053010-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-03-17 | — | — | WO | disclosed |
| EP-3860976-A1 | INDOLINONE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | ICHNOS SCIENCES S.A. (CH) | 2021-08-11 | — | — | EP | disclosed |
| WO-2020070331-A1 | INDOLINONE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | ICHNOS SCIENCES S.A. (CH) | 2020-04-09 | — | — | WO | disclosed |
| WO-2018185236-A1 | PZRAYOLE DERIVATIVES USED AS INVERSE AGONISTS OF THE ROR GAMMA (T) RETINOID-RELATED ORPHAN GAMMA RECEPTOR | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2018-10-11 | — | — | WO | disclosed |
| US-6878709-B2 | 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists | SCHERING CORPORATION (US) | 2005-04-12 | — | — | US | disclosed |
| US-20040063709-A1 | 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists | SCHERING CORPORATION | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063709-A1 | 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists | CXCR1, CCR1, ACKR3 | BAZ2B 1081/4885LMNA 4634/4885MEN1 3342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.